HEALTH
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
![Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL](https://connecticutnewspress.com/wp-content/uploads/2024/06/12097-multidrug-regimen-could-change-treatment-landscape-for-relapsed-refractory-dlbcl-780x470.jpg)
MedPage Today) — Almost 40% of patients with relapsed/refractory lymphomas achieved complete responses (CRs) with a five-drug regimen that targeted different cancer-survival pathways, a preliminary clinical trial showed.
Overall, 54% of patients…